November 24, 2016 - By Ellis Scott · 0 Comments
Allergan Inc (NYSE:AGN) institutional sentiment increased to 4 in 2016 Q2. Its up 3.54, from 0.46 in 2016Q1. The ratio has increased, as 6 active investment managers increased and started new equity positions, while 13 reduced and sold their positions in Allergan Inc. The active investment managers in our partner’s database now possess: 58,328 shares, down from 63,978 shares in 2016Q1. Also, the number of active investment managers holding Allergan Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 2 Increased: 3 New Position: 3.
The stock increased 2.25% or $4.25 on November 23, hitting $193.09. About 5.26M shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 15.73% since April 22, 2016 and is downtrending. It has underperformed by 21.14% the S&P500.
Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on February, 27. They expect $3.74 earnings per share, up 9.68% or $0.33 from last year’s $3.41 per share. AGN’s profit will be $1.37B for 12.91 P/E if the $3.74 EPS becomes a reality. After $3.32 actual earnings per share reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 12.65% EPS growth.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Mengis Capital Management Inc. holds 1.27% of its portfolio in Allergan plc Ordinary Shares for 6,210 shares. Frontier Investment Mgmt Co owns 32,758 shares or 0.94% of their US portfolio. Moreover, Mitchell Mcleod Pugh & Williams Inc has 0.83% invested in the company for 3,975 shares. The California-based Grassi Investment Management has invested 0.22% in the stock. Armstrong Henry H Associates Inc, a Pennsylvania-based fund reported 3,690 shares.#img1#
Ratings analysis reveals 78% of Allergan Inc.’s analysts are positive. Out of 18 Wall Street analysts rating Allergan Inc., 14 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $232 while the high is $400. The stock’s average target of $296.47 is 53.54% above today’s ($193.09) share price. AGN was included in 46 notes of analysts from July 29, 2015. Deutsche Bank maintained it with “Buy” rating and $278 target price in Tuesday, August 9 report. Nomura initiated Allergan plc Ordinary Shares (NYSE:AGN) on Tuesday, September 29 with “Buy” rating. The firm has “Buy” rating by Deutsche Bank given on Thursday, April 7. The rating was reinitiated by JP Morgan on Thursday, April 7 with “Overweight”. The company was upgraded on Friday, August 19 by Mizuho. The firm has “Buy” rating by Leerink Swann given on Monday, September 21. Citigroup maintained the stock with “Buy” rating in Thursday, April 7 report. The firm has “Buy” rating given on Friday, November 13 by Mizuho. The company was maintained on Tuesday, November 1 by Mizuho. The stock of Allergan plc Ordinary Shares (NYSE:AGN) has “Buy” rating given on Friday, August 7 by Deutsche Bank.
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States.
More recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. Also Investorplace.com published the news titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s news article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott